henlius biotech submitted ind of another monoclonal antibody drug
investigational new drug application (ind) of the 4th monoclonal antibody drug developed by shanghai henlius biotech co., ltd (henlius biotech) officially got the acceptance number from shanghai fda on dec. 30th, 2013. with this 5th ind application since foundation of henlius biotech four years ago, liu shigao, ceo of henlius biotech stated that we are one of the chinese manufacturers with most applications for class 2 new drugs of biologic products. henlius biotech has become the first echelon of chinese monoclonal antibody development; currently inds of four monoclonal antibody drugs and five indications are submitted.
in 2009, given the booming in chinese bio-pharmaceutical market especially the field of monoclonal antibody drugs, fosun pharma decided to enter the field of monoclonal antibody drugs. so shanghai henlius biotech co., ltd was established by heavy investment with joint efforts of a distinguished team of overseas scientists, making fosun pharma one of the pioneers in this field. outstanding talents and a first class team are always the core competencies of r&d. henlius biotech’s overseas scientists team gathers a group of senior experts with more than ten years’ experience in supervisory roles at top international pharmaceutical companies, whose expertise covers the systematic development process from upstream to downstream. from the very beginning of incorporation, henlius biotech has been taking develop quality antibody drugs to benefit global patients as its utmost mission. in the future, henlius biotech will be committed to providing patients with quality yet low-priced antibody drugs, to become a leading biopharmaceutical company in china trusted by patients and with global influence.